Background-Atrial fibrillation (AF) is a common and costly problem among older persons. The frequency of AF increases with age, but representative national data about incidence and prevalence are limited. We examined the annual incidence, prevalence, and mortality associated with AF among older persons. Methods and Results-In a retrospective cohort study of Medicare beneficiaries 65 years and older diagnosed with AF between 1993 and 2007, we measured annual age-and sex-adjusted incidence and prevalence of AF and mortality following an AF diagnosis. Among 433 123 patients with incident AF, the mean age was 80 years, 55% were women, and 92% were white. The incidence of AF remained steady during the 14-year study period, ranging from 27.3 to 28.3 per 1000 person-years. Incidence rates were consistently higher among men and white beneficiaries. The prevalence of AF increased across the study period (mean, 5% per year) and was robust to sensitivity analyses. Among beneficiaries with incident AF in 2007, 36% had heart failure, 84% had hypertension, 30% had cerebrovascular disease, and 8% had dementia. Mortality after AF diagnosis declined slightly over time but remained high. In 2007, the age-and sex-adjusted mortality rates were 11% at 30 days and 25% at 1 year. Conclusions-Among older Medicare beneficiaries, incident AF is common and has remained relatively stable for more than a decade. Incident AF is associated with significant comorbidity and mortality; death occurs in one-quarter of beneficiaries within 1 year. (Circ Cardiovasc Qual Outcomes. 2012;5:85-93.)
A trial fibrillation (AF) is the most common sustained dysrhythmia. It impairs quality of life and complicates the management of other chronic illnesses. 1 Atrial fibrillation is associated with considerable morbidity, including an increased risk of cognitive impairment, a 3-fold increase in the risk of heart failure, and a 5-fold increase in the risk of stroke. [2] [3] [4] In addition to its morbidity, AF is associated with increased mortality. 5 Consequently, AF leads to significant health care resource use and substantial economic burden. Expenditures related to AF cost Medicare approximately $16 billion annually. 6 Atrial fibrillation is a complication of many cardiopulmonary disorders that lead to increased afterload, elevated filling pressures, and left atrial enlargement. 7 Many of these precip-itating conditions are increasing in prevalence, including hypertension, obesity, and obstructive sleep apnea. 8 However, AF is also a disease of aging. Incidence doubles with each decade of life. 9 The annual incidence of AF per 1000 person-years is 1.9 in women and 3.1 in men younger than 65 years, but exceeds 32 per 1000 person-years in patients 80 years and older. Age-related declines in vascular compliance, increased population longevity, and the increasing prevalence of cardiovascular disease in older persons has led to an expanding AF epidemic.
The Institute of Medicine recently ranked treatment strategies for AF among the highest-priority topics for comparative effectiveness research. 10 Effective prevention and appropriate allocation of health care resources for the care of patients with AF require accurate estimates of disease burden in the population and its effects on mortality. Therefore, we examined trends in the incidence and prevalence of AF among Medicare beneficiaries and the burden of comorbid conditions and associated mortality among beneficiaries with incident AF.
WHAT IS KNOWN
• Atrial fibrillation (AF) is associated with considerable morbidity and mortality. • The frequency of AF increases with age, but nationally representative data about incidence and prevalence in the United States are limited. • AF leads to significant health care resource use and substantial economic burden, including annual Medicare expenditures of approximately $8 billion.
WHAT THE STUDY ADDS
• From 1993 to 2007, the incidence of AF in the Medicare population remained steady, ranging from 27.3 to 28.3 per 1000 person-years. Incidence rates were consistently higher among men and white beneficiaries. The prevalence of AF increased throughout the study period at a mean rate of 5% per year. • Mortality after AF diagnosis declined slightly but remained high; age-and sex-adjusted mortality in 2007 was 11% at 30 days and 25% at 1 year. • Incident AF is common in the Medicare population and is associated with significant comorbidity and mortality; death occurs in one-quarter of beneficiaries within 1 year.
Methods

Data Sources
We Medicare beneficiaries report race at the time of enrollment. We used the reported race categories "black" and "white" and combined all other categories as "other/unknown." The unique, encrypted beneficiary identifiers in the files enabled longitudinal follow-up throughout the study period. We limited the analysis to beneficiaries 65 years or older living in the United States. We also required beneficiaries to be enrolled in fee-for-service Medicare, because claims are not generated for research during periods of enrollment in Medicare managed care.
Incidence
We identified beneficiaries with AF on the basis of a diagnosis on a single inpatient claim or 2 outpatient or physician claims within 365 days (ICD-9-CM code 427.31 in any position on the claim). We defined the diagnosis date as the earlier of (1) the earliest discharge date for qualifying inpatient claims, or (2) the earliest service date of the second qualifying outpatient or physician claim. Consistent with previous investigations, 11, 12 we required 2 outpatient claims in order to minimize the impact of rule-out diagnoses and to improve the specificity of our definition of AF. Requiring 2 or more outpatient claims can be used to define the presence of chronic disease in Medicare claims data, 13 and this approach is used to calculate comorbid burden in Medicare. This restriction is not applied to inpatient claims, which have greater specificity. 14 To avoid classifying beneficiaries with prevalent AF as incident cases, we considered a beneficiary to have incident AF only if the diagnosis occurred after at least 2 years of enrollment in fee-forservice Medicare with no AF diagnosis. Therefore, the earliest date of incident AF we could observe was January 1, 1993.
We calculated annual incidence as the number of beneficiaries with incident AF during the year divided by the total person-years at risk among all beneficiaries that year who did not have AF at the beginning of the year. To mirror the enrollment restriction on the numerator, only person-time from beneficiaries with at least 2 years of enrollment in fee-for-service Medicare was included in the denominator. Thus, all incidence calculations reflect a population aged 67 years or older.
Prevalence
We calculated annual prevalence on December 31 of each year as the number of beneficiaries alive with AF divided by the total number of beneficiaries alive during that year. We determined that a beneficiary had prevalent AF in a given year if AF was coded as described above during that year (ie, on 1 inpatient claim or 2 outpatient claims). Only beneficiaries enrolled in fee-for-service Medicare for the entire calendar year were included in the prevalence calculations, so that we would have an opportunity to observe claims with AF. Thus, all prevalence calculations reflect a population aged 66 years or older.
Comorbid Conditions and Mortality
For patients with incident AF, we summarized comorbid conditions present at the time of the AF diagnosis. Using previously validated coding algorithms, 15, 16 we searched the inpatient, outpatient, and physician claims from the diagnosis date and from the previous 12 months for ICD-9-CM diagnosis codes for cancer, cerebrovascular disease, chronic obstructive pulmonary disease, dementia, diabetes mellitus, hypertension, ischemic heart disease, peripheral vascular disease, and renal disease. We also identified death dates, if present, in the Medicare denominator files for patients with incident AF. We did not exclude any patients from the mortality calculations. We estimated mortality using survival methods, which include each patient's follow-up data until censoring occurred because of lack of claims data. We had information on mortality through September 30, 2007.
Statistical Analysis
We calculated age-and sex-adjusted incidence and prevalence of AF overall and by sex, race, and age group. We performed the adjustments by direct standardization to the United States population aged 66 years or older in 2000 for the prevalence estimates and by direct standardization to the United States population aged 67 years or older for the incidence estimates using the following sex-specific age groups: 66 or 67 to 69 years, 70 to 74 years, 75 to 79 years, 80 to 84 years, 85 to 89 years, and 90 years or older. We used Poisson regression models to estimate annual changes in age-and sexadjusted incidence and prevalence rates and to assess the statistical significance of these trends. To examine the potential effect of claims data coding practices on the estimates, we calculated incidence and prevalence rates over time using only diagnoses from inpatient claims or only diagnoses from outpatient claims. For this sensitivity analysis only, we included patients in the numerator for both rates if they had diagnoses of AF on both inpatient and outpatient claims. We also conducted a sensitivity analysis in which we restricted the definition of prevalent AF to include only patients for whom a diagnosis of AF appeared on an inpatient claim or as the primary diagnosis on 2 outpatient claims.
For the subset of patients with incident AF, we summarized demographic characteristics and comorbid conditions using medians with interquartile ranges for continuous variables and frequency distributions for categorical variables. For all variables except race, we used Spearman rank correlations to test for significant temporal trends during the study period. We used 2 tests to test for temporal changes in the distribution of race categories. We also calculated 30-day, 1-year, and 3-year mortality rates in each incident cohort. We again used Spearman rank correlations to test for temporal trends. We calculated age-and sex-adjusted rates of comorbid conditions and mortality in this incident AF subset standardized to the population of patients with incident AF in the Medicare 5% sample in 2000. The same sex-specific age groups listed above were used. Finally, we used standardized mortality ratios to compare the observed number of deaths within 30 days, 1 year, and 3 years after incident AF with the expected number of deaths in the overall Medicare 5% sample by year, sex, and age group.
We used SAS version 9.2 for all analyses (SAS Institute Inc, Cary, NC). The institutional review board of the Duke University Health System approved the study.
Results
Incidence
In a nationally representative 5% sample of Medicare beneficiaries, the age-and sex-adjusted incidence of AF remained relatively stable at 27.3 per 1000 person-years in 1993 versus 28.3 per 1000 person-years in 2007 (PϽ0.001). Incidence was consistently higher among men and white beneficiaries and increased substantially with age ( Table 1 , Supplemental  Table 1 [see the online-only supplement]). However, the overall incidence rates remained relatively stable across all subgroups during the study period ( Figure 1 ). Table 2 shows characteristics of patients with incident AF. In 2007, the median age at diagnosis was 80.0 years (interquartile range, 74.0 to 86.0). More than 1 in 10 patients with AF were 90 years or older, and the age distributions remained relatively unchanged between 1993 and 2007. Most patients with incident AF were white (91.0%), and the distribution of race among patients with incident AF was also relatively unchanged during the study period. The prevalence of comorbid conditions increased significantly among patients with incident AF.
Prevalence
The prevalence of AF more than doubled from 41.1 per 1000 beneficiaries in 1993 to 85.8 per 1000 beneficiaries in 2007 (Table 3 , Supplemental Table 2 [see the online-only supplement], Figure 2 ). The mean annual increase in prevalence was 5.0% (PϽ0.001). Although the prevalence rate increased in all age groups, the magnitude of the increase was greater with advancing age, such that the mean annual change was 4.3% among patients 66 to 69 years and 5.4% among patients 90 years or older (PϽ0.001).
Setting of Diagnosis
We examined incident and prevalent diagnoses of AF on claims from specific health care settings ( 
Influence of Coding
To address the impact of possible changes in coding practices and the influence of potential diagnostic uncertainty on prevalence, we conducted a sensitivity analysis in which we restricted the definition of prevalent AF to include only patients for whom a diagnosis of AF appeared on an inpatient claim or as the primary diagnosis on 2 outpatient claims. With this more restrictive definition, prevalence rates were lower (68.0 per 1000 beneficiaries in 2003, and 73.2 per 1000 beneficiaries in 2007). However, the trends remained similar ( Table 5 ). When we used the a priori definition, prevalent AF increased by 5% per year compared with 4.6% under the more restrictive definition ( Table 5 ). We found that an increasing proportion of beneficiaries with prevalent AF in 1 year were coded as having prevalent AF in the next year (Supplemental Table 4 [see the online-only supplement]). Therefore, prevalent AF was more likely over time to be coded for a given patient with known AF.
Mortality
Short-term, intermediate, and long-term mortality rates were similar in 1993 and 2007 (Table 6 , Supplemental Table 5 [see the online-only supplement]). In 2003, the 30-day mortality rate after incident diagnosis of AF was 12.6% and the standardized mortality ratio was 20.2%. The 1-year mortality rate was 27.6%, or 3.5 times greater than the expected mortality. Figure 3 shows the 1-year mortality rate after incident diagnosis of AF in 2007, the last year of the study period. Age-and sex-adjusted mortality rates were 10.8% at 30 days and 24.7% at 1 year. The 3-year mortality rate did not change appreciably between 1993 and 2005, the latest incident AF cohort for which we had complete 3-year follow-up data. The 3-year standardized mortality ratio was 2.0 in 1993 and 2.0 in 2005. Mortality after an inpatient diagnosis of AF was significantly greater than mortality after an outpatient diagnosis (Supplemental 
Discussion
In a nationally representative sample of more than 3 million Medicare beneficiaries 65 years or older, the incidence of AF remained relatively stable from 1993 to 2007. Incidence increased with age, and the incidence rate was 5-fold greater among beneficiaries 90 years or older than among those 67 to 69 years. Prevalence increased across the study period and was robust to sensitivity analyses. Although the risk of mortality in the study population was high, the short-term, intermediate, and long-term mortality rates were relatively stable during the study period. Recent reports have described the prevalence of AF; 17,18 however, to our knowledge, none have examined incidence and subsequent mortality in a contemporary, nationally representative sample of older patients. Incidence of AF among Medicare beneficiaries appears to be higher than in other populations. In the Rotterdam Study, 19 incidence was 21 per 1000 person-years among persons 80 to 84 years (compared with 33 to 39 per 1000 person-years in our Medicare cohort). Similar to the Framingham study, the Cardiovascular Health Study, and others, we found that incidence was higher among men than among women in all age groups. 20, 21 Consistent with other studies, we also observed that the incidence was lower among black persons compared with white persons. 20, [22] [23] [24] Identification of racial variation in susceptibility to AF is important for several reasons, including appropriate risk stratification.
Given the fairly stable rates of incidence and mortality, the observed rise in the prevalence of AF is particularly striking. On the basis of our data, we estimate that there were 2.2 million fee-for-service Medicare beneficiaries with prevalent AF in 2007. Changes in coding practices may have artificially inflated our prevalence estimates; however, even after we applied a stricter definition of prevalent AF, we found a greater than 25% increase in prevalent AF since 1998. Epidemiological reports have identified an increase in prevalence since 1990. 25, 26 Recently, Naccarelli and colleagues 17 examined the prevalence of AF in the MarketScan national research database. They identified the prevalence of AF in 2005 between 3% among patients 65 to 69 years and almost 14% among patients 85 years or older. Similarly, the overall prevalence in our cohort in 2005 was 80/1000 beneficiaries (8%), with age-specific rates of 3.6% among patients 66 to 69 years and 16.3% among patients 85 to 89 years. Our comparison of prevalence estimates based on inpatient claims with those based on outpatient claims suggests that routine coding of AF after an incident diagnosis (ie, postincidence coding) increased during the study period. On the basis of inpatient claims alone, prevalence increased from 24.9 to 35.3 per 1000 beneficiaries. In contrast, prevalence on the basis of outpatient claims tripled from 24.8 to 74.5 per 1000 beneficiaries. Postincidence coding may reflect greater recognition of AF as an important risk factor, more frequent referral to physicians who are more likely to code an AF diagnosis (eg, cardiologists and electrophysiologists), or increasing reliance on outpatient treatment strategies. Postincidence coding also may explain the increase in prevalent AF despite relatively stable incidence and mortality rates. The increasing rates of AF also may reflect a more general form of ascertainment bias resulting from increased electrocardiographic monitoring across all health care settings. The frequency of AF among Medicare beneficiaries has important implications for health care resource use. Atrial fibrillation accounts for nearly one-quarter of all strokes among older persons and costs Medicare $16 billion per year. 6 Hospitalizations are a large component of AF-related health care costs. 28 More than 80% of patients hospitalized with AF are 65 years or older; 29 therefore, increased prevalence will lead to more short-term and intermediate-term health care expenditures among Medicare beneficiaries compared with younger patients. Our findings support the notion that hospitalizations will drive AF-related costs in the Medicare population, because most incident diagnoses of AF were associated with hospitalization.
In addition, risk factors for AF were highly prevalent among patients with new-onset AF, including heart failure, hypertension, and chronic obstructive pulmonary disease. Therefore, efforts to prevent AF should include the preven-tion of cardiopulmonary risk factors and cardiopulmonary disease in general.
Previous research has shown that a new diagnosis of AF is associated with increased mortality. In an analysis from Olmsted County, Minnesota, incident AF was associated with 23% mortality at 1 year. 30 We found similar risks, including a 1-year mortality rate of 27%. On the other hand, longerterm mortality in this Medicare population was lower than in the Olmstead County study (43% versus 63% at 3 years). This difference is surprising, especially because we limited our analysis to beneficiaries 65 years and older. However, we required beneficiaries to have 1 inpatient claim or more than 1 outpatient claim with a diagnosis of AF for inclusion in the cohort. This requirement may have led to bias in our mortality estimate. In any case, these findings suggest that 1 in 4 older patients with AF will die within a year after the diagnosis. †Under the restrictive definition of prevalent atrial fibrillation, only patients for whom a diagnosis of atrial fibrillation appeared on an inpatient claim or as the primary diagnosis on 2 outpatient claims were included in the analysis. Outpatient claims with diagnoses of atrial fibrillation not in the primary position were not considered in these calculations.
The persistence and stability of AF-related mortality during the study period serves as a reminder that few available treatment options for AF improve survival. Until recently, only warfarin was shown in randomized trials to decrease all-cause mortality among patients with AF. 31, 32 A recent study of commercially insured adults in the United States found that more than 40% of patients with AF had coronary artery disease and more than 30% had heart failure. 17 In our nationally representative sample of older patients, 51% had coronary artery disease and 36% of patients had heart failure in 2007. On the basis of age-adjusted data, the 1-year mortality rate among Medicare beneficiaries with incident AF was 25%. Also, observed mortality was greatest among those with an inpatient diagnosis of AF, suggesting that AF mortality may be related closely to underlying comorbid cardiovascular and noncardiovascular disease.
Despite a 3-fold increase in the number of clinical trials on AF management strategies, 33 there has not been an increase in the number of lifesaving treatment options. The Institute of Medicine identified research on AF treatment strategies a national priority for comparative effectiveness research. 10 Our findings provide additional support for this important call.
Our study has several limitations. Incidence and prevalence estimates from Medicare claims data are not directly comparable with estimates from medical record review. However, they do reflect the burden of AF in the Medicare program.
Second, coding practices change over time, and these changes can affect incidence and prevalence estimates. Whereas the increase in prevalent AF may have been influenced by changes in coding practices, increases in prevalence remained robust despite application of a more rigorous definition of prevalent AF. Nevertheless, additional study into the prevalence trends is merited. Third, because our study was limited to Medicare claims, beneficiaries who accessed health care services before participating in Medicare may have been classified incorrectly as incident cases if a prior diagnosis was not documented during the enrollment examination. Greater than 90% of the cohort was white. Thus, the use of these data to estimate mortality in black and other nonwhite populations may be limited. Finally, claims data are limited with respect to clinical characteristics because comorbid conditions are not uniformly coded. The large sample size and unbiased outcome (ie, all-cause mortality) in our study provide assurance that the mortality data are not spurious and accurately represent the longitudinal history of AF among older patients.
Atrial fibrillation remains a common problem among older persons. The incidence of AF has been stable for more than a decade without appreciable improvement. Older patients with AF are at high risk for mortality. Given the frequency, morbidity, and mortality associated with AF, there is a pressing need for better prevention and effective treatments with an emphasis on improved survival. 
